Renal toxicity associated with antiretroviral therapy

HIV Clinical Trials

Volumn 13, Issue 4, 2012, Pages 189-211

  Calza, Leonardo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

antiretroviral therapy; glomerular dysfunction; nephrotoxicity; screening; tenofovir; tubular dysfunction

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ADEFOVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BETA 2 MICROGLOBULIN; CIDOFOVIR; CREATININE; CYSTATIN C; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; INTERLEUKIN 1; INTERLEUKIN 6; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ZIDOVUDINE;

ABNORMAL URINE COMPOSITION; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; AMINOACIDURIA; ARTICLE; ATHEROSCLEROSIS; ATROPHY; BETA2 MICROGLOBULINURIA; BONE DENSITY; CALCIUM BALANCE; CD4 LYMPHOCYTE COUNT; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; COMORBIDITY; CRYSTALLURIA; DIABETES INSIPIDUS; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSURIA; FANCONI RENOTUBULAR SYNDROME; FLANK PAIN; GLOMERULAR DYSFUNCTION; GLOMERULUS FILTRATION RATE; GLUCOSURIA; GROUPS BY AGE; HEMATURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPHOSPHATURIA; HYPERTENSION; HYPERURICOSURIA; HYPOPHOSPHATEMIA; INTERSTITIAL NEPHRITIS; KIDNEY ATROPHY; KIDNEY CLEARANCE; KIDNEY COLIC; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PAPILLA NECROSIS; KIDNEY TUBULE ACIDOSIS; KIDNEY TUBULE DAMAGE; LABORATORY TEST; LACTIC ACIDOSIS; LIFE EXPECTANCY; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); MYOGLOBINURIC PIGMENT NEPHROPATHY; NEPHROLITHIASIS; NEPHROTOXICITY; OBSTRUCTIVE UROPATHY; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TUBULAR DYSFUNCTION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; KIDNEY; PHOSPHONIC ACIDS;

EID: 84864654197     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1304-189     Document Type: Article

References (118)

1. Winston J, Deray G, Hawkins T, Szczech L, Wyat C, Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis. 2008;47:1449-1457.
2. Cooper RD, Tonelli M. Renal disease associated with antiretroviral therapy in the treatment of HIV. Nephron Clin Pract. 2011;118:c262-c268.
3. Atta MG, Lucas GM, Fine DM. HIV-associated nephropa-thy: epidemiology, pathogenesis, diagnosis and manage-ment. Expert Rev Anti Infect Ther. 2008;6:365-371.
4. El-Sadr WM, Lundgren JD, Neaton JD, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
5. Mocroft A, Wyatt C, Szczech L, et al. Interruption of anti-retroviral therapy is associated with increased plasma cystatin C. AIDS. 2009;23:71-82.
6. Kalayjian RC, Franceschini N, Gupta SK, et al. Suppres-sion of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22:481-487.
7. Reid A, Stohr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis. 2008;46:1271-1281.
8. Deeks SG. HIV infection, inflammation, immunosenes-cence, and aging. Annu Rev Med. 2011;62:141-155.
9. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010;7:4-10.
10. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Asso-ciation of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585.
11. Winston JA. HIV and CKD epidemiology. Adv Chronic Kid-ney Dis. 2010;17:19-25.
12. Kalayjian RC. Renal issues in HIV infection. Curr HIV/AIDS Rep. 2011;8:164-171.
13. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis published online ahead of print March 23, 2012. BMC Public Health.
14. Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5:563-573.
15. Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011. http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
16. European AIDS Clinical Society. Guidelines. Version 6.0. October 2011. http://www.europeanaidsclinicalsociety.org.
17. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011;2011:354908. Epub 2011 Jun 7.
18. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773-780.
19. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22:99-103.
20. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
21. Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naïve patients. J Acquir Immune Defic Syndr. 2010;53:62-69.
22. Cockcroft DW, Gault MH. Prediction of creatinine clear-ance from serum creatinine. Nephron. 1976;16:31-41.
23. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular fil-tration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667-1678.
24. Déti EK, Thiébaut R, Bonnet F, et al. Prevalence and fac-tors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med. 2010;11:308-317.
25. Tordato F, Cozzi Lepri A, Cicconi P, et al. Evaluation of glo-merular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011;12:4-13.
26. Calza L, Trapani F, Tedeschi S, et al. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients. Scand J Infect Dis. 2011;43:656-660.
27. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496-505.
28. Scherzer R, Estrella M, Yongmei Li, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection published online ahead of print February 4, 2012. AIDS.
29. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;23:1971-1975.
30. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547-1556.
31. Dejesus E, Young B, Morales-Ramirez JO, et al. Simplifi-cation of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir diso-proxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51:163-174.
32. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized com-parison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral- naïve, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49-57.
33. Martinez E, Arranz JA, Podzamczer D, et al. A simplifica-tion trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51:290-297.
34. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus rito-navir or efavirenz as part of a three-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445-456.
35. Post FA, Wyatt CM, Mocroft A. Biomarkers of impaired renal function. Curr Opin HIV AIDS. 2010;5:524-530.
36. Hall AM, Edwards SG, Lapsley M, et al. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2009;54: 1034-1042.
37. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomeru-lar function in HIV patients treated with tenofovir. AIDS. 2009;23:689-696.
38. Kinai E, Hanabusa H. Progressive renal tubular dysfunc-tion associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009;25:387-394.
39. Calmy A, Fux CA, Norris R, et al. Low bone mineral den-sity, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009;200:1746-1754.
40. Gatanaga H, Tachikawa N, Kikuchi Y, et al. Urinary beta-2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2006;22:744-748.
41. Jaafar A, Séronie-Vivien S, Malard L, Massip P, Chatelut E, Tack I. Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. AIDS. 2009;23: 257-259.
42. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-asso-ciated renal and bone toxicity. HIV Med. 2009;10:482-487.
43. Horizon AA, Joseph RJ, Liao Q, Ross ST, Pakes GE. Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. HIV AIDS (Auckl). 2011;3:53-59.
44. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40: 1194-1198.
45. Winston A, Amin J, Mallon P, Marriott D, Carr A, Cooper DA, Emery S. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. 2006;7:105-111.
46. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular fil-tration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12:1165-1173.
47. Young B, Buchacz K, Baker RK, et al. Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Out-patient Study. J Int Assoc Physicians AIDS Care (Chic III). 2007;6:178-187.
48. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-asso-ciated renal function decline with protease inhibitor-based versus nonnucleoside reverse transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102-108.
49. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10:329-336.
50. Overton ET, Nurutdinova D, Freeman J, Seyfried W, Mondy KE. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active anti-retroviral therapy. HIV Med. 2009;10:343-350.
51. Crum-Cianflone N, Ganesan A, Teneza-Mora N, et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS. 2010;24:353-360.
52. Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir diso-proxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139:313-320.
53. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743-746.
54. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21: 1273-1281.
55. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir diso-proxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naïve patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47:74-78.
56. O'Donnell EP, Scarsi KK, Darin KM, Gerzenshtein L, Postelnick MJ, Palella FJ. Low incidence of renal impair-ment observed in tenofovir-treated patients. J Antimicrob Chemother. 2011;66:1120-1126.
57. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopi-navir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265-272.
58. Atazanavir (Reyataz) capsules prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2007.
59. Darunavir (Prezista) tablets prescribing information. Bridgewater, NJ: Tibotec, Inc; 2007.
60. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323-332.
61. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679-1688.
62. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS. 2007;21:1431-1439.
63. Kearney BP, Sayre JR, Flaherty JF, Chen SS, Kaul S, Cheng AK. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol. 2005;45:1360-1367.
64. Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szc-zech LA, Kalayjian RC. The effects of HIV type-1 viral sup-pression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. Antivir Ther. 2009;14:543-549.
65. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'Agati VD. Adefovir nephrotoxicity: possible role of mito-chondrial DNA depletion. Hum Pathol. 2001;32:734-740.
66. Birkus G, Hitchcock JM, Cihlar T. Assessment of mitochon-drial toxicity in human cells treated with tenofovir: compari-son with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46:716-723.
67. Cihlar T, LaFlamme G, Fisher R, et al. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: charac-terization of renal transport and accumulation. Antimicrob Agents Chemother. 2009;53:150-156.
68. Perazella MA. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int. 2010;78:1060-1063.
69. Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofo-vir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009;89:513-519.
70. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest. 2011;91:852-858.
71. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78: 1171-1177.
72. Maggi P, Montinaro V, Ballacosa C, et al. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS Patient Care STDS. 2012;26:5-11.
73. Rodriguez-Novoa S, Labarga P, D'Avolio A, et al. Impair-ment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010;24:1064-1066.
74. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006;194:1481-1491.
75. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predic-tors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108-e116.
76. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011;204:145-153.
77. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55:78-81.
78. Campbell LJ, Hamzah L, Post FA. Is tenofovir-related renal toxicity incompletely reversible? J Acquir Immune Defic Syndr. 2011;56:e95.
79. Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy. AIDS. 2005;19: 844-845.
80. Morris AA, Baudouin SV, Snow MH. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS. 2001;15:140-141.
81. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006;52:296-297.
82. Krishnan M, Nair R, Haas M, Atta MG. Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis. 2000;36:1075-1078.
83. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006;52:296-297.
84. Krishnan M, Nair R, Haas M, Atta MG. Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis. 2000;36:1075-1078.
85. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read. 2009;19:114-121.
86. Izzedine H, Valantin MA, Daudon M, Mohand HA, Caby F, Katlama C. Efavirenz urolithiasis. AIDS. 2007;21:1992.
87. Wirth GJ, Teuscher J, Graf JD, Iselin CE. Efavirenz-induced urolithiasis. Urol Res. 2006;34:288-289.
88. Angel-Moreno-Maroto A, Suarez-Castellano L, Hernan-dez-Cabrera M, Perez-Arellano JL. Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. J Infect. 2006;52:e39-e40.
89. Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active anti-retroviral therapy-induced nephropathy. Clin Infect Dis. 2006;42:1488-1495.
90. Daugas E, Rougier JP, Hill G. HAART-related nephrop-athies in HIV-infected patients. Kidney Int. 2005;67: 393-403.
91. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119-125.
92. Dieleman JP, Sturkenboom MC, Jambroes M, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med. 2002;162:1493-1501.
93. De Araujo M, Seguro AC Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity. Antivir Ther. 2002;7:181-184.
94. Herman JS, Ives NJ, Nelson M, Gazzard BG, Easterbrook PJ. Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother. 2001;48:355-360.
95. Casado JL, Moreno A, Sabido R, et al. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clin Trials. 2000;1: 13-19.
96. Bochet MV, Jacquiaud C, Valantin MA, Katlama C, Deray G. Renal insufficiency induced by ritonavir in HIV-infected patients. Am J Med. 1998;105:457.
97. Green ST, McKendrick MW, Schmid ML, Mohsen AH, Prakasam SF. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS. 1998;9:555.
98. Engeler DS, John H, Rentsch KM, Ruef C, Oertle D, Suter S. Nelfinavir urinary stones. J Urol. 2002;167:1384-1385.
99. Doco-Lecompte T, Garrec A, Thomas L, Trechot P, May T, Rabaud C. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS. 2004;18:705-706.
100. Important information about Lexiva (fosamprenavir calcium) tablets and oral suspension. US Food and Drug Administration. April 12, 2009. www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ ucm192905.htm.
101. Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis. 2007;45:e105-e108.
102. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Event Reporting System. AIDS. 2007;21:1215-1218.
103. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis. 2004;44:e81-e84.
104. Schmid S, Opravil M, Moddel M, et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch. 2007;450:665-670.
105. Levey AS, Stevens LA, Schmid CH, et al. A new equa-tion to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
106. Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr. 2012;59:18-24.
107. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348: 2175-2185.
108. DeJesus E, Gottlieb MS, Gathe JC Jr, Greenberg ML, Guittari CJ, Zolopa AR. Safety and efficacy of enfu-virtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. Antimicrob Agents Chemother. 2008;52:4315-4319.
109. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for pre-viously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
110. Gatell JM, Katlama C, Grinsztejn B, et al. Long-term effi-cacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr. 2010;53:456-463.
111. Levey AS, Coresh J, Balk E, et al. National Kidney Founda-tion practice guidelines for chronic kidney disease: evalu-ation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
112. Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TW, Proko-powicz D, Rogalska M, Parfieniuk A. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. Antivir Ther. 2006;11:641-645.
113. Odden MC, Scherzer R, Bacchetti P, et al. Cystatin C level as a marker of kidney function in human immunodefi-ciency virus infection: the FRAM study. Arch Intern Med. 2007;167:2213-2219.
114. Bonjoch A, Bayés B, Riba J, et al. Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antivir Res. 2010;88:347-354.
115. Vrouenraets SM, Fux CA, Wit FW, et al. A comparison of measured and estimated glomerular filtration rate in suc-cessfully treated HIV-patients with preserved renal func-tion. Clin Nephrol. 2012;77:311-320.
116. van Griensven J, Sopheak T, Koole O, Verpooten GA, Lynen L. Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used. J Acquir Immune Defic Syndr. 2011;57:e21-e22.
117. Vrouenraets SM, Fux CA, Wit FW, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS. 2011;25:2149-2155.
118. Maggi P, Bartolozzi D, Bonfanti P, et al. Renal complica-tions in HIV disease: between present and future. AIDS Rev. 2012;14:37-53.